Merck, Whitehouse Station, NJ 08889, USA.
Ann Am Thorac Soc. 2013 Feb;10(1):31-8. doi: 10.1513/AnnalsATS.201209-075PS.
There is a long history of productive collaboration between biomedical scientists in academia and in the pharmaceutical industry. The primary beneficiary of this collaboration has been the public. Since the middle of the last century, marked advances in the treatment and prevention of disease have been driven by the translational research interactions across these two domains. But now, at a time when collaboration between academia and industry should be accelerating based on past success, new technology, and ever-increasing need, numerous obstacles to effective collaboration have appeared. In this analysis, based on experience in both academia and industry, the author provides perspective on current obstacles to academic-industrial collaboration, followed by recommendations on how effective collaboration can be renewed and enhanced.
学术界和制药行业的生物医药科学家之间有着悠久的合作历史,并且卓有成效。公众是这种合作的主要受益者。自上个世纪中叶以来,这两个领域之间的转化研究互动推动了疾病治疗和预防方面的显著进步。但是现在,在过去的成功、新技术和日益增长的需求的基础上,学术界和工业界之间的合作本应加速的时候,有效的合作却出现了众多障碍。基于在学术界和工业界的经验,作者在本文中分析了当前学术-工业合作的障碍,并就如何恢复和加强有效的合作提出了建议。